7 News & Press Releases found
Evaxion Biotech A/S News
-
Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper ...
-
Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today it has received clearance ...
-
Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update
Expect to close our follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depositary Shares (ADSs) for gross proceeds of $27.6 million before deducting underwriter fees and commissions and other offering expenses ...
-
Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial ...
-
Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update
Successfully completed initial public offering on U.S. Nasdaq in February 2021, raising gross proceeds of $30 million Clinical development on track with dosing of first patient in Phase 1/2a melanoma trial of cancer vaccine EVX-02 Cash reserves ...
-
Evaxion Biotech Announces Publication of Study on S. aureus Bacterium in Scientific Reports
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper ...
-
Evaxion Biotech Closes its U.S. Initial Public Offering of American Depositary Shares
Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the closing of its initial public offering of ...